Laparoscopic sleeve gastrectomy
Intervention2 papers2 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
Funder: NSW Ministry of Health
- Humans1
- In silico1
Associations
2Quality-adjusted life years
upin silico1
1 study
Quality-adjusted life years
upin silico1
Laparoscopic sleeve gastrectomy is associated with quality-adjusted life years in silico (ICER $53,700/QALY vs semaglutide).
In silicoMarkov simulation compared to semaglutide in older adults with BMI ≥ 35 and cardiovascular disease25 years
The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment · Obesity (Silver Spring, Md.) · 7 Oct 2026
Type 2 diabetes
downin humans1
1 study
Type 2 diabetes
downin humans1
Laparoscopic sleeve gastrectomy is associated with type 2 diabetes in humans (-24.4% (148.8 to 112.5 per 1,000, p<0.001)).
Humansundergoing laparoscopic sleeve gastrectomy2017 to 2022n = 34,738
Cardiovascular Risk, Comorbidity and Frailty in Patients Undergoing Sleeve Gastrectomy: A Population-Based Study · Heart, lung & circulation · 18 Sep 2026